ArticleAnnals of clinical and translational neurology2020
Amyloid-β PET and CSF in an autopsy-confirmed cohort.
Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO.Functional & integrative genomics · 2025Pooled it
- Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies.AJNR. American journal of neuroradiology · 2025Review
- Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Review
- New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025Review
- Fluid biomarkers in familial frontotemporal dementia: progress and prospects.Frontiers in neurology · 2025Review
- Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Connecting genomic and proteomic signatures of amyloid burden in the brain.medRxiv : the preprint server for health sciences · 2024Article
- Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Direct to Consumer Biomarker Testing for Alzheimer Disease-Are We Ready for the Insurance Consequences?JAMA neurology · 2024Article
- Development of SERS Active Nanoprobe for Selective Adsorption and Detection of Alzheimer's Disease Biomarkers Based on Molecular Docking.International journal of nanomedicine · 2024Article
- Unsupervised [European journal of nuclear medicine and molecular imaging · 2023Article
- Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.JAMA network open · 2023Article
- Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.Brain : a journal of neurology · 2022Article
- Discordant Amyloid Status Diagnosis in Alzheimer's Disease.Biomedicines · 2022Article
- Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.Brain : a journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccumulation of amyloid-β is among the earliest changes in Alzheimer's disease (AD). Amyloid-β positron emission tomography (PET) and Aβ
methodsWe included 21 patients from our tertiary memory clinic who had undergone both CSF Aβ
resultsNeuropathological diagnosis was AD in 11 (52%) patients. Amyloid-β PET was positive in all A3, C2, and C3 cases and in one of the two A2 cases. CSF Aβ
interpretationOur study demonstrates neuropathological underpinnings of amyloid-β CSF/PET discordance. Furthermore, amyloid-β biomarker positivity on both PET and CSF did not invariably result in an AD diagnosis at autopsy, illustrating the importance of considering relevant comorbidities when evaluating amyloid-β biomarker results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.